Bayer 보도자료(Bayer Anounced)에서 미국 FDA2017. 5. 30. Mobile App에 대한 sBLA (supplemental Biologics License Application)을 승인 받았다는 뉴스를 전합니다. 분야는 다발성경화증(MS) 치료목적 인터페론 주사관련 digital healthcare technology입니다.

 

 

공개자료에 따른 myBETAapp™ & BETACONNECT Navigator™ 기술내용은 다음과 같습니다.

 

  • Display scheduled injections according to an injection routine
  • Allow the user to determine when an injection is scheduled
  • Display suggested injection sites based on the injection sites shown in the prescribing information for BETASERON®
  • Display a monthly calendar of recorded, missed, and scheduled injections
  • Transfer and sync data recorded by the autoinjector to the corresponding injection in the calendar
  • Send a notice to record injection data to the patient via email

 

 

작성일시 : 2017.06.16 15:00
Trackback 0 : Comment 0

댓글을 달아 주세요